Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
作者信息
Bittmann Stefan, Weissenstein Anne, Villalon Gloria, Moschuring-Alieva Elena, Luchter Elisabeth
机构信息
Department of Pediatrics, Ped Mind Institute (PMI), Gronau, Germany.
出版信息
J Clin Med Res. 2020 May;12(5):320-322. doi: 10.14740/jocmr4161. Epub 2020 May 8.
Abstract
摘要
相似文献
1
Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?丝氨酸蛋白酶抑制剂卡莫司他和/或组织蛋白酶L抑制剂联合治疗新型冠状病毒肺炎？
J Clin Med Res. 2020 May;12(5):320-322. doi: 10.14740/jocmr4161. Epub 2020 May 8.
2
Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.抑肽酶对TMPRSS2相关丝氨酸蛋白酶共价抑制机制的结构基础
J Virol. 2021 Sep 9;95(19):e0086121. doi: 10.1128/JVI.00861-21. Epub 2021 Jun 23.
3
Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.中东呼吸综合征冠状病毒通过跨膜丝氨酸蛋白酶 2（TMPRSS2）介导感染。
J Virol. 2013 Dec;87(23):12552-61. doi: 10.1128/JVI.01890-13. Epub 2013 Sep 11.
4
Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases.抑肽酶不抑制中性粒细胞丝氨酸蛋白酶的蛋白水解活性。
Pharmaceuticals (Basel). 2022 Apr 20;15(5):500. doi: 10.3390/ph15050500.
5
Protease inhibitors targeting coronavirus and filovirus entry.靶向冠状病毒和丝状病毒进入的蛋白酶抑制剂。
Antiviral Res. 2015 Apr;116:76-84. doi: 10.1016/j.antiviral.2015.01.011. Epub 2015 Feb 7.
6
The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.丝氨酸蛋白酶抑制剂卡莫司他可抑制人气管上皮细胞原代培养物中的流感病毒复制和细胞因子产生。
Pulm Pharmacol Ther. 2015 Aug;33:66-74. doi: 10.1016/j.pupt.2015.07.001. Epub 2015 Jul 10.
7
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体（RES-Q-HR）：一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
8
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.TMPRSS2 抑制剂那法莫司他可降低 COVID-19 小鼠模型中的 SARS-CoV-2 肺部感染。
mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3.
9
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.联合抑制宿主进入因子 PIKfyve 激酶和 TMPRSS2 蛋白酶对 SARS-CoV-2 感染的协同阻断。
J Virol. 2021 Oct 13;95(21):e0097521. doi: 10.1128/JVI.00975-21. Epub 2021 Aug 18.
10
A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.一项评估甲磺酸达比加群酯（DWJ1248）治疗成人轻度至中度 COVID-19 患者的有效性和安全性的双盲、随机、安慰剂对照、II 期临床研究。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0045222. doi: 10.1128/aac.00452-22. Epub 2022 Dec 14.
引用本文的文献
1
Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study.甲磺酸卡莫司他及其主要代谢产物的安全性评价和群体药代动力学：一项I期研究
Pharmaceutics. 2023 Sep 21;15(9):2357. doi: 10.3390/pharmaceutics15092357.
2
The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets.先天性免疫反应、微环境蛋白酶与COVID-19大流行：病理生理机制及新出现的治疗靶点
Kidney Int Suppl (2011). 2022 Apr;12(1):48-62. doi: 10.1016/j.kisu.2021.12.001. Epub 2022 Mar 18.
3
Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures.局部抑制 TMPRSS2 可预防人呼吸道分化细胞中 SARS-CoV-2 的感染。
Life Sci Alliance. 2022 Feb 2;5(4). doi: 10.26508/lsa.202101116. Print 2022 Apr.
4
Long non-coding RNAs (lncRNAs) NEAT1 and MALAT1 are differentially expressed in severe COVID-19 patients: An integrated single-cell analysis.长链非编码 RNA（lncRNA）NEAT1 和 MALAT1 在重症 COVID-19 患者中表达差异：一项综合单细胞分析。
PLoS One. 2022 Jan 10;17(1):e0261242. doi: 10.1371/journal.pone.0261242. eCollection 2022.
5
Regulating monocyte infiltration and differentiation: Providing new therapies for colorectal cancer patients with COVID-19.调节单核细胞浸润和分化：为新冠肺炎合并结直肠癌患者提供新疗法。
World J Clin Cases. 2021 Dec 6;9(34):10392-10399. doi: 10.12998/wjcc.v9.i34.10392.
6
Neurological complications and infection mechanism of SARS-COV-2.SARS-COV-2 的神经系统并发症和感染机制。
Signal Transduct Target Ther. 2021 Nov 23;6(1):406. doi: 10.1038/s41392-021-00818-7.
7
SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection.严重急性呼吸综合征冠状病毒 2 型：了解 ACE2 和 TMPRSS2 的转录调控，以及 p53 密码子 72 处单核苷酸多态性（SNP）在固有免疫反应对病毒感染中的作用。
Int J Mol Sci. 2021 Aug 12;22(16):8660. doi: 10.3390/ijms22168660.
8
Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by α-1 Antitrypsin.脂多糖和 SARS-CoV-2 刺突蛋白增强人 PBMCs 的促炎活性由α-1 抗胰蛋白酶调节。
Int J Mol Sci. 2021 Jul 26;22(15):7941. doi: 10.3390/ijms22157941.
9
Serine protease inhibitors could be of benefit in the treatment of COVID-19 disease.丝氨酸蛋白酶抑制剂可能对治疗新冠肺炎有益。
Ther Adv Infect Dis. 2021 Jul 13;8:20499361211032048. doi: 10.1177/20499361211032048. eCollection 2021 Jan-Dec.
10
Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options.丝氨酸蛋白酶和宿主细胞受体在新冠病毒蛋白水解激活、进入过程中的作用及其当前治疗选择
Infect Drug Resist. 2021 May 24;14:1883-1892. doi: 10.2147/IDR.S308176. eCollection 2021.
本文引用的文献
1
Cytokine release syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子释放综合征
Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17.
2
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.一种口服生物利用度的广谱抗病毒药物可抑制人呼吸道上皮细胞培养中的 SARS-CoV-2 病毒和小鼠中的多种冠状病毒。
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
3
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
4
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.2019-nCoV 对口腔黏膜上皮细胞 ACE2 受体的高表达。
Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x.
5
Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease.卡莫司他通过抑制一种通道激活蛋白酶，在体内减弱气道上皮钠通道功能。
J Pharmacol Exp Ther. 2009 May;329(2):764-74. doi: 10.1124/jpet.108.148155. Epub 2009 Feb 3.
6
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.组织蛋白酶L抑制剂可阻止严重急性呼吸综合征冠状病毒进入。
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81. doi: 10.1073/pnas.0505577102. Epub 2005 Aug 4.
7
Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity.
Lab Invest. 2005 Jan;85(1):75-89. doi: 10.1038/labinvest.3700203.
8
Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry.严重急性呼吸综合征相关冠状病毒（SARS-CoV）刺突糖蛋白介导的病毒进入的特征
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5. doi: 10.1073/pnas.0306446101. Epub 2004 Mar 9.
Zotero 插件